Tight Control of Gouty Arthritis Compared to Usual Care

Официальное название

Effect of Tight Urate Control in Gouty Arthritis Compared to Usual Care (TICOGA), a Randomised Clinical Trial

Обзор

Gout is caused by a reaction to urate crystals that results in attacks of severe joint pain. Medicines that lower urate levels can prevent gout flares, however it takes time for this benefit to be felt, and paradoxically starting treatment with large doses of urate lowering treatment risks provoking attacks of gout. Medical guidelines disagree on the best way to overcome these challenges with many recommending medicine dose adjustment based on regular urate testing but a general practice guideline suggesting more simply increasing the medicine dose in those patients that continue to suffer flares. In reality most patients are not treated at all, and many of those that are treated never receive an effective dose of treatment. We have developed a supported self-management approach to gout in which patients monitor their own urate levels using a finger prick test, and then receive advice on adjusting their treatment dose to achieve target urate levels through a smartphone app (Gout SMART). A trial of this approach has shown that it results in much better control of urate levels after 6 months than usual care, and suggests that it also leads to fewer flares. We would now like to confirm that this approach is effective in reducing flares of gout over 2 years by randomising patients to either treatment-to-target urate using our self-monitoring approach, or to usual care.

Подробное описание

A total of approximately 125 participants will be recruited. We anticipate that most participants will be identified following referral to rheumatology outpatient or on-call services in National Health Service (NHS) Lothian, or through NHS Lothian's gout liaison service. Additional patients may indicate their willingness to participate directly in response to study advertisements.

Based on baseline renal function and flare frequency, an individual treatment plan will be drawn up for all participants which will set a ceiling on the maximum dose of allopurinol to be used within the trial and determine the need for flare prophylaxis with colchicine. Participants will be randomized to the intervention group in a 1:1 ratio, with stratification by the need for use of flare prophylaxis.

All participants will have a smart phone application (GoutSMART) uploaded to their smart phones. Usual care participants will have a limited version of the GoutSMART application installed which includes background information about gout and provides a means for participants to maintain diaries of gout flares. Subjects in the usual care arm of the study will have treatment escalation decisions made by their GPs. Subjects in the treat-to-target arm will be taught to self-test serum urate using a BeneCheck Plus hand held device and provided with test strips. A full version of the GoutSMART application will be installed with the features mentioned above but also the facility to record a urate diary. Participants will be prompted to check their serum urate and enter the results into the GoutSMART application. Participants reporting a urate level \>0.3mmol/l will be advised to increase the dose of allopurinol incrementally as specified in their treatment plan. No change will be advised in those whose urate levels are already at target. If the patient needs to increase allopurinol there will be an automatic reminder after two weeks prompting the patients to submit updated self-test results which will be handled in the same way as described above. Conversely for participants achieving target levels this will be acknowledged and a request to resubmit readings will be sent on a monthly basis.

Вмешательства

• Другое Treat-to-target
  Treatment to achieve urate target using supported self-management approach
• Другое Usual Care
  Treatment escalation by GP based on usual clinical practice

Первичные конечные точки

• Proportion of participants flare free in 2nd year of trial [Срок оценки: 2nd year of trial]

Вторичные конечные точки (12)

• Number of flares of gout [Срок оценки: 2 years]
• Urate targets of ≤0.3mmol/L or ≤0.36mmol/L [Срок оценки: 2 years]
• Presence of tophi [Срок оценки: 2 years]
• Societal cost [Срок оценки: 2 years]
• Time to remission [Срок оценки: 2 years]
• User engagement [Срок оценки: 2 years]
• Medication prescriptions [Срок оценки: 2 years]
• Quality of life using SF-36 questionnaire [Срок оценки: 2 years]
• Activity limitation [Срок оценки: 2 years]
• Medication compliance [Срок оценки: 2 years]
• Cost-effectiveness [Срок оценки: 2 years]
• Cost-Utility [Срок оценки: 2 years]

Критерии участия

Критерии включения

• Provision of informed consent.
• Age ≥18 years.
• Patient has sustained at least one flare of gout in the previous 12 months.
• Confirmed clinical diagnosis of gout as per ACR/EULAR criteria
• Serum urate \>0.36mm/L.
• Patient has a smart phone and is able to install GoutSMART application.

Критерии исключения

• Subject unable to provide consent
• Patient on maximum urate lowering therapy or where therapy cannot be escalated further due to intolerance/adverse reaction to either allopurinol or febuxostat.
• End stage renal failure/transplant
• Current prescription of medication known to interact with xanthine oxidase inhibitors such as azathioprine or mercapto-purine.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Открытое

Основная цель

Организация здравоохранения

Центры проведения

Великобритания · 1 центр

• NHS Lothian — Edinburgh

Публикации

• Riches PL, Alexander D, Hauser B, Kuske B, Krause A. Evaluation of supported self-management in gout (GoutSMART): a randomised controlled feasibility trial. Lancet Rheumatol. 2022 May;4(5):e320-e328. doi: 10.1016/S2665-9913(22)00062-5. Epub 2022 Mar 24. PMID 38294032

Идентификаторы

NCT: NCT05507723 · AC22077

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗